55 - BC200 RNA Changes in Breast Cancer Patients After Treatment

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 50

Janine Harewood, MD1; Jia Yee, MD1; Henri Tiedge, PhD1; Bret Wankel1; Victoria Forte, MD2; Nora Chokr, MD1; Charles Kim, MD3; Ilham Muslimov, MD, PhD1

1State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, NY

2NYC Health + Hospitals, New York, NY

3NYU Langone Health, New York, NY

Background

Regulatory brain cytoplasmic 200 RNA (BC200 RNA) is a nucleotide RNA transcript found under normal conditions in the brain that inhibits the initiation of translation. It has recently been found to be associated with numerous cancer cells, including human mammary carcinoma cells. Iacoangeli and colleagues previously demonstrated that quantitative reverse-transcription polymerase chain reaction methods could be used as the basis for a blood test for BC200 RNA in patients with invasive breast cancer.1 They were able to demonstrate high sensitivity and specificity of blood levels of BC200 RNA and suggested it could be used as a circulating tumor cell marker (CTC). What is not known is how this marker changes over time and with treatment. Our objective is to investigate how BC200 RNA blood levels in patients with breast cancer correlate with treatment and to establish whether monitoring BC200 RNA in patients’ blood will be useful for evaluating treatment outcomes.

Materials and Methods

We are recruiting all newly diagnosed patients with locally advanced and metastatic breast cancer (aged 18 to 100 years) from the year 2019 and ongoing in a tertiary institution to our study. Treatment interventions are provider dependent. Patients with known genetic conditions are excluded from the study, as are patients who have already had a treatment intervention before the first blood sample was drawn for the study. Blood samples are to be collected at the time of diagnosis, monthly during chemotherapy, after surgery, and every 6 months thereafter. Primary outcomes include assessment of the change in BC200 RNA blood levels over time and with treatment interventions.

Status

The study is open, with ongoing recruitment. Twenty-two participants have been recruited at time of submission. Currently, all patients have had an initial blood sample. Due to COVID-19, follow-up sample collections have been sporadic. One patient has withdrawn from the study and 1 patient has died since starting the study.

Reference:

  1. Iacoangeli A, Adzovic L, Chen EQ, Latif Cattie R, Soff GA, Tiedge H. Regulatory BC200 RNA in peripheral blood of patients with invasive breast cancer. J Investig Med. 2018;66(7):1055-1063. doi: 10.1136/jim-2018-000717
Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content